Histone deacetylases (HDAC) inhibitors in breast cancer therapy
A detailed description of histone deacetylases (HDAC) inhibitors
(vorinostat, panobinostat, entinostat, belinostat, valproic acid) that
are currently used in routine therapy or are in clinical trials in
breast cancer patients.
In « Molecular Therapy of Breast Cancer: Classicism Meets Modernity ».
by Marc Lacroix
InTextoResearch, Baelen (Liège, Wallonia), Belgium
Nova Sciences Publishers, New York, ISBN 978-1-60741-593-0